One company currently in the US DoJ’s sights is Pfizer, which in a recent filing with the Securities and Exchange Commission said it had volunteered information to both the DoJ and the SEC about “potentially improper payments” related to sales activities outside the USA – and had been doing so since 2004. While the company would not discuss the implications of the DoJ investigation for its UK business, it is adamant that strong procedures have been introduced to prevent recurrence, and that it has invested “substantial resources” in compliance programmes including mandatory training, proactive monitoring and surveillance.
via pharmatimes.com
No comments:
Post a Comment